Dose-dependent decreases in tumor growth rates were found in an additional MCA205 study, for an AZD4635 dose range of 10–50 mg/kg, in combination with the anti-PD-L1 mAb, although confidence intervals overlapped among these groups (see Figure 1C; and Supplementary Materials, Figure S6). This evidence concerns the gene CD274 and neoplasm.